Skip to content

Investigation of the Effects of Prehabilitation Education Delivered Through a Mobile Compatible Website on Quality of Life and Symptoms in Patients Undergoing Hematopoietic Stem Cell Transplantation

Investigation of the Effects of Prehabilitation Education Delivered Through a Mobile Compatible Website on Quality of Life and Symptoms in Patients Undergoing Hematopoietic Stem Cell Transplantation

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07066592
Enrollment
36
Registered
2025-07-15
Start date
2024-12-13
Completion date
2025-08-15
Last updated
2025-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological Malignancy, Patient Education, Prehabilitation

Keywords

prehabilitation, quality of life, bone marrow transplantation, education

Brief summary

Aim of the Study: The aim of this study is to examine the effect of prehabilitation education delivered via a mobile-compatible website on the quality of life and symptom evaluation of patients undergoing hematopoietic stem cell transplantation (HSCT). Research Questions: What is the effect of prehabilitation education delivered via a mobile-compatible website on the quality of life of stem cell transplant patients? What is the effect of prehabilitation education delivered via a mobile-compatible website on the symptom management of stem cell transplant patients? Method: In this study, patients will be randomly assigned to one of two groups: One group will receive prehabilitation education through a mobile-compatible website. The other group will receive standard educational procedures.

Detailed description

Hematopoietic Stem Cell Transplantation (HSCT) is an intensive treatment with the potential to cure hematologic malignancies and other highly morbid diseases. However, it is also associated with significant risks of morbidity and mortality. Many HSCT patients experience a variety of physical, emotional, and cognitive symptoms, particularly during the acute recovery phase following transplantation. Gastrointestinal symptoms such as nausea, vomiting, loss of appetite, mucositis, and changes in taste often emerge during the pre-transplant conditioning period and may persist for an extended period after the transplant. Loss of strength and pain are among the most common and severe symptoms during the acute recovery phase. Other frequently encountered symptoms include anorexia, loss of muscle mass, and fatigue. During hospitalization, HSCT patients may also experience clinically significant emotional symptoms such as anxiety, depression, or adjustment disorders. These symptoms can negatively impact patients' subjective symptom burden, treatment adherence, and length of hospital stay. Therefore, accurate assessment and management of symptoms and risks during hospitalization are essential to minimize the symptom burden in HSCT patients. Since HSCT involves high-dose chemotherapy, prolonged hospital stays, and strict isolation protocols, transplant-specific quality of life (QoL) assessment is crucial. Evaluating QoL in transplant patients can help healthcare professionals understand patients' physical, psychological, and social well-being and identify their rehabilitation needs. Numerous symptoms caused by the disease and HSCT, as well as transplant-specific complications, significantly reduce patients' quality of life and adversely affect long-term transplant outcomes. For this reason, it is important to prepare patients adequately before undergoing HSCT. In such cases, the concept of prehabilitation is considered essential. Prehabilitation is a clinical model that introduces rehabilitation components to patients before intensive medical interventions, aiming to optimize functionality and improve tolerance to treatment. Cancer prehabilitation is a part of the cancer rehabilitation care process. It occurs between the time of cancer diagnosis and the start of acute treatment. It includes physical and psychological assessments to establish a baseline functional level, identify impairments, and provide interventions that promote psychological health and physical improvement to reduce the incidence and/or severity of future impairments. The aim of this study is to investigate the effect of prehabilitation education provided via a mobile-compatible website on the quality of life and symptom evaluation of patients undergoing HSCT. Patients will be randomly assigned to two groups: one group will receive prehabilitation education via a mobile-compatible website, while the other group will receive standard education procedures. Both groups will be assessed using the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) and the Edmonton Symptom Assessment Scale (ESAS) on the day of hospital admission, the day of transplantation, and the day of discharge. The web-based educational content consists of 9 sections: What is stem cell transplantation? Pre-transplant preparation period Stem cell transplantation procedure and engraftment What is oral mucositis (mouth sores)? How to perform oral care? What is the risk of infection? How to protect yourself from infection? Side effects of transplant treatment Nutrition and food preparation after transplantation Returning home after stem cell transplantation and home exercise suggestions before transplant At the end of the study, the test results of the patient groups will be compared both within and between groups. The study aims to determine whether the group receiving prehabilitation education through a mobile-compatible website differs significantly from the group receiving standard education and to evaluate the impact of the educational intervention on patient outcomes.

Interventions

BEHAVIORALPrehabilitation education provided via mobile compatible website

The prehabilitation education delivered through a mobile-compatible website was developed specifically for patients who are candidates for stem cell transplantation. Through this platform, patients can easily and quickly access accurate information on managing potential symptoms during the transplant process, as well as guidance on nutrition and exercise aimed at improving their quality of life.

Sponsors

Ankara Oncology Research and Training Hospital
CollaboratorNETWORK
Saglik Bilimleri Universitesi
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Undergoing Hematopoietic Stem Cell Transplantation (HSCT) for the first time * Having no musculoskeletal problems that would prevent physical activity * Volunteering to participate in the study * Between 18 and 70 years of age * Having access to and the ability to use a mobile phone and the internet * Literate in Turkish (able to read and write in Turkish)

Exclusion criteria

* Having a condition that prevents effective communication * Being illiterate (unable to read and write) * Inability to use technology

Design outcomes

Primary

MeasureTime frameDescription
symptom managementThe baseline and average 3-4 weeksEdmonton Symptom Assessment Scale. Each symptom is evaluated using numerical ratings ranging from 0 to 10. A score of 0 indicates that the symptom is absent, while a score of 10 indicates that the symptom is felt very severely. The severity of the symptom increases progressively from 0 to 10. (The changes will be evaluated from the baseline level to the day of transplantation and up to the day of discharge. This period takes approximately 3-4 weeks on average)
quality of functionalityThe baseline and average 3-4 weeksFunctional Assessment of Cancer Therapy-Bone Marrow Transplant (4th version) The minimum score obtainable from the FACT-BMT scale is 0, and the maximum score is 148. Higher scores indicate a better quality of life. (The changes will be evaluated from the baseline level to the day of transplantation and up to the day of discharge. This period takes approximately 3-4 weeks on average)

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026